Vertex Pharmaceuticals Incorporated Deal History & Licensing Activity
Vertex Pharmaceuticals Incorporated is a large pharma headquartered in US. Over the past three years, Vertex Pharmaceuticals Incorporated has been involved in 8 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (4 deals). The company currently has 50 active clinical trials, primarily in Rare Disease.
Deals (12mo)
3
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Rare Disease
Vertex Pharmaceuticals Incorporated Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Vertex Pharmaceuticals Incorporated in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| T-cell engager / multispecific antibody platform | AbCellera Biologics Inc. | Bispecific Antibodies | Discovery | collaboration | Jul 29, 2026 |
| Hypercon technology | Vertex Pharmaceuticals | Other | Unknown | collaboration | Apr 7, 2026 |
| Trispecific T-cell engager (TCE) | Vertex Pharmaceuticals | Bispecific Antibodies | Preclinical | license | Feb 2, 2026 |
Vertex Pharmaceuticals Incorporated Pipeline Focus
Therapeutic areas and modalities where Vertex Pharmaceuticals Incorporated is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Vertex Pharmaceuticals Incorporated Clinical Pipeline
Vertex Pharmaceuticals Incorporated has 50 active clinical trials across 7 development phases.
4
Phase 4
2
Unknown
6
Phase 1
6
Phase 1/2
9
Phase 2
2
Phase 2/3
21
Phase 3
See How Your Asset Matches Vertex Pharmaceuticals Incorporated's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Vertex Pharmaceuticals Incorporated Licensing & Deal Activity
Vertex Pharmaceuticals Incorporated is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Vertex Pharmaceuticals Incorporated ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Vertex Pharmaceuticals Incorporated include Rare Disease (19 deals and trials), Renal (9 deals and trials), CNS Disorders (9 deals and trials), and Immunology (6 deals and trials). In terms of modality, Vertex Pharmaceuticals Incorporated has shown particular interest in bispecific antibodies, other, cell therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Vertex Pharmaceuticals Incorporated and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Vertex Pharmaceuticals Incorporated's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.